KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income (2016 - 2025)

Historic Net Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Net Income rose 32504.62% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 11311.16%. This contributed to the annual value of -$278.2 million for FY2024, which is 3681.73% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Net Income stood at $251.1 million, which was up 32504.62% from -$66.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Net Income high stood at $251.1 million for Q3 2025, and its period low was -$405.9 million during Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Net Income averaged around -$135.5 million, with its median value being -$174.1 million (2023).
  • Over the last 5 years, Alnylam Pharmaceuticals' Net Income had its largest YoY gain of 32504.62% in 2025, and its largest YoY loss of 29242.7% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Net Income stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then skyrocketed by 399.76% to $251.1 million in 2025.
  • Its Net Income stands at $251.1 million for Q3 2025, versus -$66.3 million for Q2 2025 and -$57.5 million for Q1 2025.